EL7.AI
StocksMedium•15 October 2026•
1 min read

Revolution Medicines Gets Positive EU CHMP Opinion for Pancreatic Cancer Drug RASONQUE

Key Facts

1The CHMP adopted a positive opinion recommending marketing authorization for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma.
2Phase 3 RASolute 302 trial results demonstrated a 60% reduction in risk of death compared with chemotherapy.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for Revolution Medicines' drug RASONQUE for the treatment of metastatic pancreatic adenocarcinoma. GlobeNewswire reported that the recommendation applies to adult patients who failed prior therapy, following Phase 3 RASolute 302 trial results that demonstrated a 60% reduction in the risk of death compared with chemotherapy.

Clinical data showed a median overall survival of 13.2 months for RASONQUE patients versus 6.7 months for the chemotherapy group, alongside significant improvements in progression-free survival. In the equity markets, RVMD closed at $193.52 on October 14, 2026, having traded between a day low of $185.88 and a high of $197 during that session.